Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Endogenous Protein C Activation with AB002 Improves Outcomes in a Rat Model of Acute Ischemic Stroke

Norah G. Verbout, Wenri Zhang, Erik I. Tucker, Andras Gruber

Blood (2023) 142 (Supplement 1): 3949.

https://doi.org/10.1182/blood-2023-187448

Published: 2023

Journal Articles

The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial

Christina U. Lorentz, Erik I. Tucker, Norah G. Verbout, Joseph J. Shatzel, Sven R. Olson, Brandon D. Markway, Michael Wallisch, Martina Ralle, Monica T. Hinds, Owen J. T. McCarty, David Gailani, Jeffrey I. Weitz, András Gruber

Blood (2021) 138 (22): 2173–2184.

https://doi.org/10.1182/blood.2021011725

Published: 2021

Includes: Supplemental data

Journal Articles

A Phase 2 Trial of the Protein C Activator AB002 in End-Stage Renal Disease Patients on Chronic Hemodialysis

Norah G Verbout, Christina U Lorentz, Brandon D Markway, Michael Wallisch, Joseph J Shatzel, Andras Gruber, Erik I Tucker

Blood (2021) 138 (Supplement 1): 669.

https://doi.org/10.1182/blood-2021-148208

Published: 2021

Journal Articles

Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial

Christina U Lorentz, PhD, Norah G Verbout, PhD, Joseph J Shatzel, MD, Michael Wallisch, PhD, Brandon D Markway, PhD, Monica T Hinds, PhD, Owen J T McCarty, PhD, David Gailani, MD, Jeffrey I. Weitz, MDFRCPC, Erik I Tucker, PhD, András Gruber, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-139948

Published: 2020

Journal Articles

The protein C activator AB002 rapidly interrupts thrombus development in baboons

Erik I. Tucker, Norah G. Verbout, Brandon D. Markway, Michael Wallisch, Christina U. Lorentz, Monica T. Hinds, Joseph J. Shatzel, Leslie A. Pelc, David C. Wood, Owen J. T. McCarty, Enrico Di Cera, András Gruber

Blood (2020) 135 (9): 689–699.

https://doi.org/10.1182/blood.2019002771

Published: 2020

Includes: Supplemental data

Journal Articles

Safety and Antithrombotic Efficacy of the Recombinant Protein C Activator AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

Norah G Verbout, PhD, Christina U Lorentz, PhD, Brandon D Markway, PhD, Joseph J Shatzel, MD, Erik I Tucker, PhD, Andras Gruber, MD

Blood (2019) 134 (Supplement_1): 2433.

https://doi.org/10.1182/blood-2019-124999

Published: 2019

Journal Articles

Inhibition of Factor XIIa-Mediated Factor XI Activation Reduces Infarct Size in a Mouse Model of Myocardial Ischemia and Reperfusion

Christina U Lorentz, PhD, Norah G Verbout, PhD, Zhiping Cao, Helen Liu, Owen J.T. McCarty, PhD, Erik I. Tucker, PhD, Andras Gruber, MD, Donna Van Winkle, PhD

Blood (2014) 124 (21): 2873.

https://doi.org/10.1182/blood.V124.21.2873.2873

Published: 2014

Journal Articles

Rapid Interruption Of Occlusive Thrombus Formation By The Protein C Activator Enzyme EWE Thrombin (ProCase) In Primates

Erik I Tucker, PhD, Michael Wallisch, PhD, Philberta Y Leung, PhD, Andras Gruber, MD, Enrico Di Cera, MD, Norah G Verbout, PhD

Blood (2013) 122 (21): 202.

https://doi.org/10.1182/blood.V122.21.202.202

Published: 2013

Journal Articles

Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis

Erik I. Tucker, Norah G. Verbout, Philberta Y. Leung, Sawan Hurst, Owen J. T. McCarty, David Gailani, András Gruber

Blood (2012) 119 (20): 4762–4768.

https://doi.org/10.1182/blood-2011-10-386185

Published: 2012

Journal Articles

Apple Domain-Specific Anti-Factor XI Antibodies Inhibit Venous-Type Thrombosis with Improved Hemostatic Safety Profiles Compared to Enoxaparin in Primates

Erik I. Tucker, PhD, Ulla M Marzec, MS, Philberta Y Leung, PhD, Stephen R Hanson, PhD, Prof., Norah G Verbout, PhD, Sawan Hurst, MS, Owen J.T. McCarty, PhD, David Gailani, MD, Andras Gruber, MD

Blood (2011) 118 (21): 1173.

https://doi.org/10.1182/blood.V118.21.1173.1173

Published: 2011

NARROW

Endogenous Protein C Activation with AB002 Improves Outcomes in a Rat Model of Acute Ischemic Stroke

The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial

A Phase 2 Trial of the Protein C Activator AB002 in End-Stage Renal Disease Patients on Chronic Hemodialysis

Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial

The protein C activator AB002 rapidly interrupts thrombus development in baboons

Safety and Antithrombotic Efficacy of the Recombinant Protein C Activator AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

Inhibition of Factor XIIa-Mediated Factor XI Activation Reduces Infarct Size in a Mouse Model of Myocardial Ischemia and Reperfusion

Rapid Interruption Of Occlusive Thrombus Formation By The Protein C Activator Enzyme EWE Thrombin (ProCase) In Primates

Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis

Apple Domain-Specific Anti-Factor XI Antibodies Inhibit Venous-Type Thrombosis with Improved Hemostatic Safety Profiles Compared to Enoxaparin in Primates

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only